Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles

John M Gregson, Daniel F Freitag, Praveen Surendran, Nathan O Stitziel, Rajiv Chowdhury, Stephen Burgess, Kaptoge Stephen, Pei Gao, James R Staley, Peter Willeit, Sune F Nielsen, Muriel Caslake, Stella Trompet, Linda M Polfus, Kari Kuulasmaa, Jukka Kontto, Markus Perola, Stefan Blankenberg, Giovanni Veronesi, Francesco GianfagnaSatu Mannisto, Akinori Kimura, Honghuang Lin, Dermot F Reilly, Mathias Gorski, Vladan Mijatovic, CKDGen consortium, Patricia B Munroe, Georg B Ehret, International Consortium for Blood Pressure, Alex Thompson, Maria Uria-Nickelsen, Anders Malarstig, Abbas Dehghan, CHARGE inflammation working group, Thomas F Vogt, Taishi Sasaoka, Fumihiko Takeuchi, Norihiro Kato, Yoshiji Yamada, Frank Kee, Martina Muller-Nurasyid, Jean Ferrieres, Dominique Arveiler, Philippe Amouyel, Veikko Salomaa, Eric Boerwinkle, Simon G Thompson, Ian Ford, J Wouter Jukema, Naveed Sattar, Chris J Packard, Abdulla al Shafi Majumder, Dewan S Alam, Panos Deloukas, Heribert Schunkert, Nilesh J Samani, Sekar Kathiresan, MICAD Exome consortium, Borge G Nordestgaard, Danish Saleheen, Joanna M M Howson, Emanuele Di Angelantonio, Adam S Butterworth, John Danesh, EPIC-CVD consortium, CHD Exome+ consortium

Research output: Contribution to journalArticle (Academic Journal)peer-review

28 Citations (Scopus)
380 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science